10x Genomics, Inc. - Pioneer in Single Cell and Spatial Biology Technologies

Company Overview (Updated April 2026)

10x Genomics, Inc. is a life science technology company headquartered in Pleasanton, California, USA. Founded in 2012 by Serge Saxonov (CEO), Ben Hindson, and Kevin Ness, the company has established itself as a leader in single cell and spatial biology. 10x Genomics builds products to accelerate the mastery of biology and advance human health, serving academic researchers, translational research institutions, and biopharmaceutical companies worldwide. The company employs approximately 1,178 people as of 2025.

Mission: To build products that accelerate the mastery of biology and advance human health by enabling researchers to understand biological systems at a resolution and scale that matches the complexity of biology.

Financial Performance (2025)

Full Year 2025 Results

Revenue: $642.8 million (5% increase from $610.8 million in 2024). Excluding $44.1 million in non-recurring revenue related to patent litigation settlements, full-year revenue was $598.7 million, representing a 2% decrease from 2024.

Gross Margin: 69% (compared to 68% in 2024), driven by higher license and royalty revenue and improved cost management.

Operating Loss: $61.0 million (significantly improved from $194.6 million operating loss in 2024).

Net Loss: $43.5 million (compared to net loss of $182.6 million in 2024).

Operating Expenses: $504.9 million (down 17% from $609.0 million in 2024), reflecting cost discipline including the May 2025 workforce reduction.

Cash Position: $523.4 million in cash, cash equivalents, and marketable securities as of December 31, 2025 (increase of $130.0 million from prior year).

Fourth Quarter 2025 Highlights

- Q4 Revenue: $166.0 million (up 1% from Q4 2024)

- Q4 EPS: -$0.13 (missed analyst estimate of -$0.10 by 30%)

- Consumables Revenue: $141.7 million (up 6% year-over-year), driven by 14% growth in spatial consumables and 3% growth in single cell consumables

- Instruments Revenue: $15.5 million (down 36% year-over-year), reflecting continued capital expenditure constraints in the academic research sector

Revenue Breakdown by Platform (2025)

Single Cell (Chromium):

- Instruments: $22.7 million

- Consumables: $363.2 million

Spatial (Visium & Xenium):

- Instruments: $34.1 million

- Consumables: $144.0 million (Xenium drove double-digit growth; Visium flat in 2025)

Technology Platforms

Chromium (Single Cell Analysis)

The Chromium platform enables single cell transcriptomics, immune profiling, and epigenetic analysis at massive scale.

Key Products:

- Chromium Flex: Launched in 2022, the first and only commercial single cell assay compatible with FFPE (formalin-fixed paraffin-embedded) samples. Now available on GEM-X architecture enabling analysis of millions of cells for less than $0.01 per cell.

- Chromium FLEX APEX: Launched Q4 2024, designed for mega-scale CRISPR screens, cell atlasing projects, and multi-site translational studies with 30%+ volume growth in Q4 2025.

- GEM-X Flex Gene Expression: Ultra-low cost, high-throughput single cell analysis platform.

Visium (Spatial Transcriptomics)

Visium enables spatial gene expression profiling to map where genes are expressed in tissue sections.

Key Updates:

- Visium HD 3': Began shipping in 2025, expanding the platform's capabilities with high-resolution, high-sensitivity profiling.

- HD Cell Segmentation: Launched 2025, enabling more precise cell boundary identification in spatial analyses.

- Strategic Position: While Visium did not grow in 2025, it remains important for specific customer use cases. Company is strategically prioritizing Xenium for the majority of spatial analysis applications.

Xenium (In Situ Spatial Analysis)

Xenium is an in situ platform for subcellular resolution spatial analysis, capable of profiling hundreds to thousands of RNA targets directly in tissue samples.

Performance:

- Delivered double-digit consumables revenue growth in 2025.

- Considered the "best choice for spatial analysis for the vast majority of use cases" by management.

- Customers report high utilization rates, with instruments running around the clock.

- Continued new customer adoption even in a capital expenditure-constrained environment.

Strategic Partnerships & Collaborations (2025-2026)

AI and Cancer Research:

- Cancer Research Institute & PharosAI: Partnership to build some of the world's largest AI-ready datasets for cancer research, leveraging Chromium and Xenium platforms to transform thousands of clinical samples into high-resolution multimodal insights for drug discovery and diagnostics.

- PerturbAI CRISPR Brain Atlas: Collaboration with NVIDIA and leading research institutes to release a massive in vivo CRISPR brain atlas, highlighting 10x Genomics' tools as core infrastructure for cutting-edge AI-driven genomics research.

Clinical Diagnostics Development:

- Dana-Farber Cancer Institute: Multi-year collaboration to analyze patient tumor samples, incorporating single cell and spatial tumor analysis into potential diagnostic workflows to support cancer patient care.

- Brigham & Women's Hospital: Study to identify single cell blood-based signatures of autoimmune disease activity and treatment response to support clinical care.

Academic & Research Collaborations:

- Genome Institute of Singapore: TISHUMAP initiative leveraging Xenium and AI to uncover novel biomarkers and therapeutic targets for cancer and inflammatory diseases.

- Arc Institute: Partnership to accelerate development of the Arc Virtual Cell Atlas using Chromium Flex technology to generate high-quality single cell data at large scale.

Acquisitions & Strategic Moves

Scale Biosciences Acquisition (August 2025)

10x Genomics entered into a definitive agreement to acquire Scale Biosciences for upfront cash and stock consideration of $30 million, plus contingent consideration upon achievement of certain milestones.

Strategic Rationale:

- Strengthens company's leadership in single cell analysis.

- Adds key technology for more powerful, affordable, and scalable experiments (combinatorial indexing and quantum barcoding).

- Expands access to single cell analysis across broader applications.

- Expected to drive innovation in high-throughput capabilities and open new high-value markets.

Corporate Restructuring (2025)

May 2025 Workforce Reduction:

On May 12, 2025, 10x Genomics announced an 8% reduction in global workforce to adjust to "chaos gripping the American science ecosystem." The company cited "increasingly unpredictable customer purchasing behavior," with 40-50% of revenue normally supported by U.S. academic and government research funding. The restructuring is expected to save over $50 million annually.

Corporate Information (2026)

Company Profile

Company Name: 10x Genomics, Inc.

Founded: 2012

Headquarters: Pleasanton, California, USA

CEO: Serge Saxonov (Co-founder)

CFO: Adam Taich

CTO: Michael Schnall-Levin (Founding Scientist)

Employees: 1,178 (as of 2025)

Stock Symbol: TXG (Nasdaq)

Industry: Life Science Tools / Biotechnology

Website: www.10xgenomics.com

Global Presence

2025 Revenue by Geography:

- Americas: $358.8 million (55.8%) — United States: $346.5 million

- Europe, Middle East and Africa: $161.7 million (25.2%)

- Asia-Pacific: $122.3 million (19.0%) — China: $70.3 million

2026 Stock Performance & Analyst Sentiment

Recent Analyst Actions:

- Barclays (April 2026): Maintained Overweight rating, raised price target to $30.00 (from $17.00), citing recovering end markets and under-owned tools space

- Bank of America (Jan 2026): Raised target to $18 from $15, expecting headwinds to fade

- Canaccord Genuity (Jan 2026): Lifted price target to $20

Insider Activity:

- CEO Serge Saxonov executed multiple stock sales in March 2026 (totaling 29,292 shares at prices ranging from $19.13-$23.18)

- ARK Invest (Cathie Wood) sold over 473,000 shares in March 2026, creating sentiment pressure

Consensus Rating: Hold (62% of analysts), with 30% recommending Buy/Strong Buy and 8% Strong Sell

2026 Strategic Priorities & Outlook

Growth Drivers

- AI-Driven Demand: Expecting significant growth in perturb-seq applications and AI-ready dataset generation, with FLEX APEX positioned as the optimal assay for these large-scale projects.

- Spatial Biology Expansion: Continued double-digit growth expected in Xenium consumables as the platform becomes the standard for spatial analysis.

- Clinical Applications: Progressing from research tools to diagnostic workflows through partnerships with leading cancer institutes.

- Cost Discipline: Maintaining operational efficiency with improved profitability targets while protecting the strong balance sheet ($523M cash).

Challenges & Considerations

- Funding Environment: Continued uncertainty in U.S. academic and government research funding affects instrument purchasing decisions (40-50% of revenue exposed).

- Capital Expenditure Constraints: Double-digit decline in instrument revenue reflects cautious spending by academic customers.

- china Market: Approximately $70M revenue exposure with potential tariff and geopolitical considerations.

- Skeptical Analysts: Some pessimistic analysts expect revenue to shrink to ~$641M by 2028 with continued losses, contrasting with more optimistic views.

Key Differentiators

- Technology Leadership: Continuous innovation extending the gap between 10x Genomics and competitors in single cell and spatial analysis.

- Integrated Solutions: End-to-end platforms combining instruments, consumables, and software for seamless workflows.

- Scalability: GEM-X Flex enables analysis of millions of cells at under $0.01 per cell, democratizing access to single cell analysis.

- Clinical Translation: Strategic partnerships moving beyond research into diagnostic and clinical care applications.

- Financial Strength: Strong cash position ($523M) providing flexibility for acquisitions, R&D investment, and weathering market uncertainties despite near-term growth challenges.

Keywords: 10x Genomics,TXG,single cell,spatial biology,Chromium,Visium,Xenium,FLEX,GEM-X,transcriptomics,genomics,Pleasanton,Serge Saxonov,life science,AI-ready data,perturb-seq,cancer research,Dana-Farber,TISHUMAP,Scale Biosciences,PerturbAI,CRISPR,ARK Invest